Moons ago I was a Nokia shareholder. Yes I was :(
I thought that Nokia had no possible competitors. Market cap so huge it accounted for the bulk of Finland's index. Invincible.
Boom. I and all of Nokia management and all the analysts on whose reports I relied on did not see the disruptive platform coming along. Boom. Bye bye.
I still own BMY. But the one company which (if successful) could indeed be absolutely disruptive to any BioPharma is Precigen's ability to redose and unleash high delivery payloads. All monogenic and polygenic diseases will be within their reach.
As I told you once if a patient had 2 options which of the following will he/she select:
1. Take Opdivo for many years and hope for the best before relapse; or
2. Take an overnight treatment (once) with a high payload delivery which ensures persistence should you relapse well knowing that redosing is possible.
If Sangamo/ Pfizer were to announce today that their hemophilia SB-525 treatment will permit redosing they would wipe out Biomarin. In fact I made this tweet today to test the waters and I roped in the top ex US hemophilia KOL Prof Makris. See who pressed like.